Nivolumab recommended as a second-line treatment option for patients with two types of non-small-cell lung cancer
NICE draft guidance means patients with advanced squamous or non-squamous NSCLC will now be eligible for the second-line treatment on the NHS.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via